TScan Therapeutics (TCRX) Profit After Tax (2020 - 2026)

TScan Therapeutics (TCRX) has reported Profit After Tax for 7 consecutive years, with -$28.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 16.0% year-over-year to -$28.7 million; the TTM figure through Mar 2026 stood at -$124.3 million (up 5.43% YoY), while the FY2025 annual figure was -$129.8 million, down 1.8% from the prior year.
• Profit After Tax slipped to -$28.7 million in Q1 2026 per TCRX's latest filing, from -$23.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$15.1 million in Q2 2022 and bottomed at -$37.0 million in Q2 2025.
• Historically, Profit After Tax has averaged -$26.0 million across 5 years, with a median of -$24.0 million in 2023.
• Annual changes were most pronounced in 2022 — Profit After Tax tumbled 104.75% — and 2025, when it jumped 35.74%.
• TScan Therapeutics' Profit After Tax stood at -$18.7 million in 2022, then decreased by 4.9% to -$19.6 million in 2023, then tumbled by 82.54% to -$35.8 million in 2024, then surged by 35.74% to -$23.0 million in 2025, then dropped by 24.58% to -$28.7 million in 2026.
• Business Quant data shows TCRX's Profit After Tax at -$28.7 million in Q1 2026, -$23.0 million in Q4 2025, and -$35.7 million in Q3 2025.